The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
emtricitabine, rilpivirine and tenofovir disoproxil fumarate · Tablet, Film Coated
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 200 mg; HYDROCHLORIDE 25 mg; 300 mg · Tablet, Film Coated · #30 tablet, film coateds/bottle
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $114.50 · middle half $114.50–$114.50 · full range $114.50–$114.50 · 1 products · 1 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for emtricitabine, rilpivirine and tenofovir disoproxil fumarate, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- Price downNADAC $114.68136 → $114.503 per unit (-0.16%)
- Price downNADAC $114.99236 → $114.68136 per unit (-0.27%)
Same drug class
Other molecules FDA puts in Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- doravirine, islatravir· 1 maker
- emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide· 1 maker
- emtricitabine, rilpivirine, tenofovir disoproxil fumarate· 1 maker
- dolutegravir sodium and rilpivirine hydrochloride· 2 makers
- doravirine, lamivudine, and tenofovir disoproxil fumarate· 2 makers
- efavirenz, lamivudine and tenofovir disoproxil fumarate· 2 makers
- emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate· 2 makers
- doravirine· 5 makers
- efavirenz, emtricitabine and tenofovir disoproxil fumarate· 7 makers
- rilpivirine· 7 makers
- rilpivirine hydrochloride· 8 makers
- nevirapine· 10 makers
Common questions
- Is Emtricitabine, rilpivirine and tenofovir disoproxil fumarate in shortage right now?
- No. FDA does not currently list Emtricitabine, rilpivirine and tenofovir disoproxil fumarate in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Emtricitabine, rilpivirine and tenofovir disoproxil fumarate?
- 1 company has marketed Emtricitabine, rilpivirine and tenofovir disoproxil fumarate in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Emtricitabine, rilpivirine and tenofovir disoproxil fumarate cost?
- The typical pharmacy pays about $114.50 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.